These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 30610419

  • 41. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.
    Fryzek JP, Martone WJ, Groothuis JR.
    Adv Ther; 2011 Mar; 28(3):195-201. PubMed ID: 21327753
    [Abstract] [Full Text] [Related]

  • 42. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
    Roy Á, Polazzi S, Ploin D, Gillet Y, Javouhey E, Lina B, VRS study group in LyonHospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de Réanimation Pédiatrique et d'Accueil des Urgences, Bron 69500, France., Myard-Dury AF, Couray-Targe S, Duclos A, Casalegno JS.
    Vaccine; 2023 Jun 07; 41(25):3796-3800. PubMed ID: 37198017
    [Abstract] [Full Text] [Related]

  • 43. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.
    Chen JJ, Chan P, Paes B, Mitchell I, Li A, Lanctôt KL, CARESS investigators.
    PLoS One; 2015 Jun 07; 10(8):e0134711. PubMed ID: 26237402
    [Abstract] [Full Text] [Related]

  • 44. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 07; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 45. Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis.
    Butt ML, Elliott L, Paes BA.
    Paediatr Child Health; 2018 Nov 07; 23(7):441-446. PubMed ID: 30374219
    [Abstract] [Full Text] [Related]

  • 46. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.
    Pediatr Pulmonol; 2008 Feb 07; 43(2):169-74. PubMed ID: 18085710
    [Abstract] [Full Text] [Related]

  • 47. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
    Groves HE, Jenkins L, Macfarlane M, Reid A, Lynn F, Shields MD.
    Pediatr Pulmonol; 2016 Apr 07; 51(4):379-85. PubMed ID: 26808981
    [Abstract] [Full Text] [Related]

  • 48. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J, Goldstein M, Krilov LR, Wade SW, Kong AM, Brannman L.
    Hum Vaccin Immunother; 2021 May 04; 17(5):1536-1545. PubMed ID: 33090914
    [Abstract] [Full Text] [Related]

  • 49. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study.
    Sheridan-Pereira M, Murphy J, Sloan J, Crispino G, Leahy A, Corcoran JD, Dempsey E, Elnazir B, Gavin P, Sharif F, Gul R, Satas S, Murphy J, Gormally S, Shanaa I, Waldron D, Mc Mahon P, Carson J, Blanken M, Bont L, Paes B.
    Pediatr Infect Dis J; 2016 Jan 04; 35(1):19-24. PubMed ID: 26379160
    [Abstract] [Full Text] [Related]

  • 50. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
    Ozyurt A, Narin N, Baykan A, Argun M, Pamukcu O, Zararsiz G, Sunkak S, Uzum K.
    Pediatr Pulmonol; 2015 Oct 04; 50(10):1025-32. PubMed ID: 25156973
    [Abstract] [Full Text] [Related]

  • 51. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X.
    BMC Infect Dis; 2017 Oct 17; 17(1):687. PubMed ID: 29041909
    [Abstract] [Full Text] [Related]

  • 52. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA, Odelola OA, Saldanha I, McKoy N.
    Cochrane Database Syst Rev; 2010 Feb 17; (2):CD007743. PubMed ID: 20166098
    [Abstract] [Full Text] [Related]

  • 53. Respiratory syncytial virus associated hospitalizations in children with congenital diaphragmatic hernia.
    Resch B, Liziczai K, Reiterer F, Freidl T, Haim M, Urlesberger B.
    Pediatr Neonatol; 2018 Apr 17; 59(2):184-188. PubMed ID: 28887119
    [Abstract] [Full Text] [Related]

  • 54. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.
    Makari D, Checchia PA, Devincenzo J.
    Hum Vaccin Immunother; 2014 Apr 17; 10(3):607-14. PubMed ID: 24316863
    [Abstract] [Full Text] [Related]

  • 55. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B, Egger B, Kurath-Koller S, Urlesberger B.
    Int J Infect Dis; 2017 Apr 17; 57():50-53. PubMed ID: 28163166
    [Abstract] [Full Text] [Related]

  • 56. Hospitalisations due to respiratory syncytial virus infection in children with Down syndrome before and after palivizumab recommendation in Japan.
    Okamoto K, Morio T, Nakamura Y, Hataya H, Mizuta K, Mori M.
    Acta Paediatr; 2021 Apr 17; 110(4):1299-1306. PubMed ID: 33119906
    [Abstract] [Full Text] [Related]

  • 57. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA, Odelola OA, Saldanha IJ.
    Cochrane Database Syst Rev; 2016 Jul 20; 7(7):CD007743. PubMed ID: 27439110
    [Abstract] [Full Text] [Related]

  • 58. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H, Chung CH, Lin YJ, Lin CH.
    PLoS One; 2018 Jul 20; 13(5):e0197410. PubMed ID: 29746578
    [Abstract] [Full Text] [Related]

  • 59. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs.
    Pediatr Pulmonol; 2002 Sep 20; 34(3):181-8. PubMed ID: 12203846
    [Abstract] [Full Text] [Related]

  • 60. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
    Health Technol Assess; 2008 Dec 20; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.